UY27452A1 - Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer - Google Patents

Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer

Info

Publication number
UY27452A1
UY27452A1 UY27452A UY27452A UY27452A1 UY 27452 A1 UY27452 A1 UY 27452A1 UY 27452 A UY27452 A UY 27452A UY 27452 A UY27452 A UY 27452A UY 27452 A1 UY27452 A1 UY 27452A1
Authority
UY
Uruguay
Prior art keywords
cancer treatment
substituted benzimidazol
compounds
benzimidazol compounds
substituted
Prior art date
Application number
UY27452A
Other languages
English (en)
Inventor
Francois Hamy
Francois Clerc
Isabelle Depaty
Odile Boniface
Stephanie Deprets
Chantal Carrez
Manfred Roesner
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of UY27452A1 publication Critical patent/UY27452A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Nuevos compuestos de benzimidazol y su uso como inhibidores de las cinasas dependientes de la ciclina, y nuevas composiciones farmacológicas que contienen los mismos.
UY27452A 2001-09-26 2002-09-24 Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer UY27452A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01402460A EP1298125A1 (en) 2001-09-26 2001-09-26 Substituted benzimidazole compounds and their use for the treatment of cancer

Publications (1)

Publication Number Publication Date
UY27452A1 true UY27452A1 (es) 2003-02-28

Family

ID=8182891

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27452A UY27452A1 (es) 2001-09-26 2002-09-24 Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer

Country Status (35)

Country Link
US (1) US7041668B2 (es)
EP (2) EP1298125A1 (es)
JP (1) JP4510450B2 (es)
KR (1) KR100891439B1 (es)
CN (1) CN100346786C (es)
AR (1) AR037096A1 (es)
AT (1) ATE386517T1 (es)
AU (1) AU2002337151B2 (es)
BR (1) BR0212856A (es)
CA (1) CA2461622C (es)
CO (1) CO5570675A2 (es)
CY (1) CY1107953T1 (es)
DE (1) DE60225159T2 (es)
DK (1) DK1432417T3 (es)
EA (1) EA006802B1 (es)
ES (1) ES2301682T3 (es)
GT (1) GT200200190A (es)
HK (1) HK1068551A1 (es)
HR (1) HRPK20040293B3 (es)
HU (1) HUP0401756A3 (es)
IL (1) IL161059A0 (es)
ME (1) MEP16808A (es)
MX (1) MXPA04002042A (es)
MY (1) MY135339A (es)
NO (1) NO327008B1 (es)
NZ (1) NZ531246A (es)
PA (1) PA8555501A1 (es)
PE (1) PE20030427A1 (es)
PL (1) PL369527A1 (es)
PT (1) PT1432417E (es)
RS (1) RS50896B (es)
SI (1) SI1432417T1 (es)
UY (1) UY27452A1 (es)
WO (1) WO2003028721A2 (es)
ZA (1) ZA200401887B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20070208166A1 (en) * 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
EP1598348A1 (en) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
EP1836161B1 (en) 2004-12-22 2016-07-20 BHI Limited Partnership Methods and compositions for treating amyloid-related diseases
UA92180C2 (en) * 2005-09-06 2010-10-11 Смиткляйн Бичам Корпорейшн Benzimidazole thiophene compounds as plk inhibitors
FR2891273B1 (fr) * 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
PL2089417T3 (pl) 2006-10-12 2015-07-31 Bhi Lp Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
KR20100090769A (ko) * 2007-10-12 2010-08-17 아보트 러보러터리즈 2-((ｒ)-2-메틸피롤리딘-2-일)-1ｈ-벤즈이미다졸-4-카복스아미드 결정형 1
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
FR2941951B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2011091152A1 (en) * 2010-01-22 2011-07-28 Pablo Gastaminza Inhibitors of hepatitis c virus infection
CN114469984A (zh) 2015-08-25 2022-05-13 阿尔尼拉姆医药品有限公司 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2441201C2 (de) * 1974-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Anthelminthisch wirksame 2-Carbalkoxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole und Verfahren zu ihrer Herstellung
DE2541752A1 (de) * 1975-09-19 1977-03-24 Hoechst Ag Anthelminthisch wirksame 2-carbalkoxyamino-5(6)-phenyl-sulfonyloxy- benzimidazole und verfahren zu ihrer herstellung
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
WO2003028721A3 (en) 2003-12-11
PL369527A1 (en) 2005-05-02
HK1068551A1 (en) 2005-04-29
GT200200190A (es) 2003-11-11
MEP16808A (en) 2010-06-10
HRP20040293A2 (en) 2005-06-30
MY135339A (en) 2008-03-31
KR20040048904A (ko) 2004-06-10
RS50896B (sr) 2010-08-31
DE60225159D1 (de) 2008-04-03
DK1432417T3 (da) 2008-06-16
HUP0401756A3 (en) 2005-06-28
EA200400475A1 (ru) 2004-08-26
KR100891439B1 (ko) 2009-04-03
NO20041214L (no) 2004-06-24
CA2461622C (en) 2008-12-02
US7041668B2 (en) 2006-05-09
CN100346786C (zh) 2007-11-07
NO327008B1 (no) 2009-04-06
PT1432417E (pt) 2008-05-23
WO2003028721A2 (en) 2003-04-10
NZ531246A (en) 2006-06-30
HRPK20040293B3 (en) 2007-06-30
EP1432417B1 (en) 2008-02-20
EA006802B1 (ru) 2006-04-28
CO5570675A2 (es) 2005-10-31
SI1432417T1 (sl) 2008-08-31
ES2301682T3 (es) 2008-07-01
BR0212856A (pt) 2004-09-14
ATE386517T1 (de) 2008-03-15
AR037096A1 (es) 2004-10-20
EP1432417A2 (en) 2004-06-30
YU21404A (sh) 2006-08-17
CY1107953T1 (el) 2013-09-04
JP2005504112A (ja) 2005-02-10
HUP0401756A2 (hu) 2005-01-28
AU2002337151B2 (en) 2007-04-26
CA2461622A1 (en) 2003-04-10
EP1298125A1 (en) 2003-04-02
DE60225159T2 (de) 2009-02-19
MXPA04002042A (es) 2004-06-07
ZA200401887B (en) 2005-05-31
US20050014811A1 (en) 2005-01-20
JP4510450B2 (ja) 2010-07-21
PE20030427A1 (es) 2003-06-20
CN1558761A (zh) 2004-12-29
IL161059A0 (en) 2004-08-31
PA8555501A1 (es) 2003-06-30

Similar Documents

Publication Publication Date Title
UY27452A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
UY28342A1 (es) Nuevos compuestos
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
SV2003000925A (es) Derivados espirotriciclicos nuevos y su uso como inhibidores de fosfodiesterasa-7
UY28513A1 (es) Nuevos compuestos
AR067505A1 (es) Derivados de pirimidinil-piridazinona
CO6541643A2 (es) Derivados de imidazopirina como inhibidores de jak
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
GT200600166A (es) Derivados de cromano y cromeno y usos de los mismos
PA8657501A1 (es) Derivados de piperida y su uso como agentes antiinflamatorios
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
SV2008001369A (es) Benzimidazoles
UY28876A1 (es) Compuestos de morfolina sustituida y composiciones para el tratamiento de trastornos del sistema nervioso central
UY30748A1 (es) Compuesto0s novedosos
UY29685A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen.
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
UY27894A1 (es) Derivados de cinamida.
AR025078A1 (es) Utilizacion de agentes antagonistas del cgrp e inhibidores de la liberacion del cgrp para combatir sofocos menopausicos
CR7961A (es) Compuestos de aminoheteroarilo como inhibidores de las proteinquinasas
ECSP066931A (es) Nuevos imidazoles